Evidence map›Paper›PMID 33772212›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.

Edaise M da Silva, Daniel J Fix, Ana Paula Martins Sebastiao, Pier Selenica, Lorenzo Ferrando, Sarah H Kim, Anthe Stylianou, Arnaud Da Cruz Paula, Fresia Pareja, Evan S Smith and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 110 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025
    Review
  18. Controversies in the Management of Mesonephric and Mesonephric-Like Adenocarcinomas of the Female Genital Tract.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 3 countries.

Edaise M da Silva *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3281-7333
Daniel J Fix *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ana Paula Martins SebastiaoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lorenzo FerrandoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4025-7930
Sarah H KimGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anthe StylianouGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnaud Da Cruz PaulaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fresia ParejaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3748-8049
Evan S SmithGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5406-4104
Jason A KonnerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karen CadooDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2969-3173
Nadeem R Abu-RustumGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer J MuellerGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weigeltb@mskcc.org.ORCID 0000-0001-9927-1270
Kay J ParkDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. parkk@mskcc.org.ORCID 0000-0001-8989-2938
Memorial Sloan Kettering Cancer Center · USHackensack University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
CLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3M
NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS T32 CA009512
6 · The paper itself

Abstract

Mesonephric carcinoma of the cervix is a rare tumor derived from Wolffian remnants. Mesonephric-like carcinomas of the ovary and endometrium, while morphologically similar, do not have obvious Wolffian derivation. Here, we sought to characterize the repertoire of genetic alterations in primary mesonephric and mesonephric-like carcinomas, in the distinct histologic components of mixed cases, as well as in matched primary tumors and metastases. DNA from microdissected tumor and normal tissue from mesonephric carcinomas (cervix, n = 8) and mesonephric-like carcinomas (ovarian n = 15, endometrial n = 13) were subjected to sequencing targeting 468 cancer-related genes. The histologically distinct components of four cases with mixed histology and four primary tumors and their matched metastases were microdissected and analyzed separately. Mesonephric-like carcinomas were underpinned by somatic KRAS mutations (25/28, 89%) akin to mesonephric carcinomas (8/8, 100%), but also harbored genetic alterations more frequently reported in Müllerian tumors. Mesonephric-like carcinomas that lacked KRAS mutations harbored NRAS (n = 2, ovary) or BRAF (n = 1, endometrium) hotspot mutations. PIK3CA mutations were identified in both mesonephric-like (8/28, 28%) and mesonephric carcinomas (2/8, 25%). Only mesonephric-like tumors harbored CTNNB1 hotspot (4/28, 14%) and PTEN (3/13, 23%) mutations. Copy number analysis revealed frequent gains of chromosomes 1q and 10 in both mesonephric (87% 1q; 50% chromosome 10) and mesonephric-like tumors (89% 1q; 43% chromosome 10). Chromosome 12 gains were more frequent in ovarian mesonephric-like carcinomas, and losses of chromosome 9 were more frequent in mesonephric than in mesonephric-like carcinomas (both p = 0.01, Fisher's exact test). The histologically distinct components of four mixed cases were molecularly related and shared similar patterns of genetic alterations. The progression from primary to metastatic lesions involved the acquisition of additional mutations, and/or shifts from subclonal to clonal mutations. Our findings suggest that mesonephric-like carcinomas are derived from a Müllerian substrate with differentiation along Wolffian/mesonephric lines.

Indexed as

AdultAgedFemaleGenital Neoplasms, FemaleHumansMesonephromaMiddle AgedMutation

Identifiers

PMID33772212
PMCPMC8343944
OpenAlexW3139371178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.